Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy

Moeller, Benjamin J.; Rana, Vishal; Cannon, B.; Williams, Michelle D.; Ginsberg, Lawrence E.; Macapinlac, Homer A.; Lee, John; Ang, K. Kian; Chao, K.S. Clifford; Chronowski, Gregory M.; Frank, Steven J.; Morrison, William H.; Rosenthal, David I.; Weber, Randal S.; Garden, Adam S.; Lippman, Scott M.; Schwartz, David L.

doi:10.1016/j.ijrobp.2009.08.063

Cited by 19 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high SUVMax in post treatment was correlated with a poor outcome in 6 studies (Horiuchi et al, 2008;Hoshikawa et al, 2011;Ito et al, 2014;Kim et al, 2016;Kitagawa et al, 2003;Moeller et al, 2010). In (Moeller et al, 2010), 98 patients underwent a PET before and 8 weeks after RT +/− CT. The authors found that a post-treatment SUVMax ≤ 6 g/ml and the variation of SUVMax (in%) between the pre-and post-irradiation PET/CT were predictive for DFS.…”

Section: Predictive Value Of 18fdg Pet After Treatmentmentioning

confidence: 99%

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Castelli

Bari

Depeursinge

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

International audience18 F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) allows to quantify the metabolic activity of a tumor (glycolysis) and has become a reference tool in oncology for the staging, restaging, radiotherapy planning and monitoring response in many cancers. Quantitative analyses have been introduced in order to overcome some of the limits of the visual methods, allowing an easier and more objective comparison of the inter- and intra-patients variations. The aims of this review were to report available evidences on the clinical value of quantitative PET/CT parameters in HNC. Forty-five studies, for a total of 2928 patients, were analyzed. Most of the data available dealt with the intensity of the metabolism, calculated from the Standard Uptake Value (SUV). Metabolic Tumor Volume (MTV) was well correlated with overall survival and disease free survival, with a higher predictive value than the maximum SUV. Spatial distribution of metabolism and textural analyses seems promising

show abstract

Section: Predictive Value Of 18fdg Pet After Treatmentmentioning

confidence: 99%

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Castelli

Bari

Depeursinge

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…Between 2005 and 2007, 107 consecutive locally advanced head and neck cancer patients receiving definitive radiotherapy were screened for enrollment onto a previously described prospective IRB-approved imaging trial (MDACC LAB 07-0043) (6, 7). Screened patients were eligible for enrollment if they were 18 years of age and had biopsy-proven American Joint Commission on Cancer (AJCC) version 6 stage II-IVb squamous cell carcinoma of the pharyngolaryngeal axis.…”

Section: Methodsmentioning

confidence: 99%

Metabolic Imaging Biomarkers of Postradiotherapy Xerostomia

Cannon

Schwartz

Dong

2012

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Purpose Xerostomia is a major complication of head and neck radiotherapy. Available xerostomia measures remain flawed. FDG-PET/CT is routinely used for staging and response assessment of head and neck cancer. We investigated quantitative measurement of parotid gland FDG uptake as a potential biomarker for post-radiotherapy xerostomia. Methods and Materials Ninety-eight locally advanced head and neck cancer patients receiving definitive radiotherapy underwent baseline and post-radiotherapy FDG-PET/CT on a prospective imaging trial. A separate validation cohort of 14 patients underwent identical imaging while prospectively enrolled onto a second trial collecting sialometry and patient-reported outcomes. Radiation dose and pre/post-RT SUVs for all voxels contained within parotid gland regions-of-interest were deformably registered. Results Average whole gland or voxel-by-voxel models incorporating parotid DMet (defined as the pre-treatment parotid SUV weighted by dose) accurately predicted post-treatment changes in parotid FDG uptake (e.g. fractional parotid SUV). Fractional loss of parotid FDG uptake closely paralleled early parotid toxicity defined by post-treatment salivary output (p < 0.01) and RTOG/EORTC xerostomia scores (p < 0.01). Conclusions In this pilot series, loss of parotid FDG uptake strongly associates with acute clinical post-radiotherapy parotid toxicity. DMet may potentially be used to guide function-sparing treatment planning. Prospective validation of FDG-PET/CT as a convenient, quantifiable imaging biomarker of parotid function is warranted and ongoing.

show abstract

“…Between2005and2007,98stageII-IVBHNCpatientsreceiving definitive IMRT ± chemotherapy had 18 F-FDG-PET and a contrast-enhanced CT scan at baseline and 8 weeks after RT [23]. The only parameters correlating significantly with cause-specific survival (CSS) were the maximum standardized uptake value (SUVmax) of the primary tumor on follow-upandthepercentagechangeinprimarytumorSUVmax between scans.…”

Section: Applications Of Imaging: Adaptive and 4d-rtmentioning

confidence: 99%

“…On multivariate analysis, metabolic and anatomic primary tumor responses were independently predictive of outcome. The primary tumor, but not the LN response, stratified patients into clinic-radiologic risk groups [23].…”

Section: Applications Of Imaging: Adaptive and 4d-rtmentioning

confidence: 99%

Radiotherapy for Head and Neck Cancer: An Increasing Dependence on Innovative Imaging

Nuyts¹,

Fairchild²

2012

Onkologie

View full text Add to dashboard Cite

Technical improvements in computed tomography and magnetic resonance imaging as well as the wider availability of biological imaging have facilitated the implementation of high-precision 3-dimensional conformal and intensity-modulated radiotherapy (RT) in head and neck cancer. The integration of recent advances in functional and molecular imaging has already improved RT delivery, response prediction, and follow-up. Rational clinical use of all modalities should be encouraged, especially in the setting of imaging-intensive investigational RT protocols such as adaptive therapy. An expanded development of imaging markers that can predict radioresistance or outcome could further customize treatment. The continued successful use of innovative imaging in routine clinical practice will ultimately depend on well-designed clinical studies with adequate follow-up.

show abstract

Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy

Cited by 19 publications

References 29 publications

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Metabolic Imaging Biomarkers of Postradiotherapy Xerostomia

Radiotherapy for Head and Neck Cancer: An Increasing Dependence on Innovative Imaging

Contact Info

Product

Resources

About